IDEAYA Biosciences, Inc. financial data

Symbol
IDYA on Nasdaq
Industry
Pharmaceutical Preparations
Location
5000 Shoreline Ct, Suite 300, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.07K % +53.9%
Debt-to-equity 4.05 % -54.2%
Return On Equity -20.5 % -7.49%
Return On Assets -19.7 % -12.5%
Operating Margin -1.6K % -752%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.5M shares +46.8%
Common Stock, Shares, Outstanding 76.1M shares +32.5%
Entity Public Float 1.3B USD +164%
Common Stock, Value, Issued 8K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 78M shares +38.6%
Weighted Average Number of Shares Outstanding, Diluted 78M shares +38.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 12M USD -73.5%
Research and Development Expense 170M USD +63.1%
General and Administrative Expense 33.5M USD +30%
Operating Income (Loss) -191M USD -126%
Nonoperating Income (Expense) 37.6M USD +255%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -154M USD -107%
Earnings Per Share, Basic -2.18 USD/shares -47.3%
Earnings Per Share, Diluted -2.18 USD/shares -47.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 183M USD +78%
Marketable Securities, Current 519M USD +32.7%
Assets, Current 713M USD +42.1%
Property, Plant and Equipment, Net 7.12M USD +4.29%
Operating Lease, Right-of-Use Asset 1.31M USD -24.7%
Other Assets, Noncurrent 75K USD -30.6%
Assets 974M USD +84.6%
Accounts Payable, Current 15.9M USD +171%
Employee-related Liabilities, Current 5.41M USD +20.2%
Accrued Liabilities, Current 24.3M USD +65.1%
Contract with Customer, Liability, Current 1.44M USD -86%
Liabilities, Current 40.7M USD +60.8%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 1.26M USD +107%
Liabilities 42M USD +61.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.42M USD -20.1%
Retained Earnings (Accumulated Deficit) -441M USD -53.6%
Stockholders' Equity Attributable to Parent 932M USD +85.7%
Liabilities and Equity 974M USD +84.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.8M USD -57.4%
Net Cash Provided by (Used in) Financing Activities 349M USD +11831%
Net Cash Provided by (Used in) Investing Activities -354M USD -1605%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 76.1M shares +32.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -48.7M USD -3389%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 184M USD +77.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 12K USD -7.69%
Deferred Tax Assets, Valuation Allowance 95.9M USD +50.4%
Deferred Tax Assets, Gross 96.5M USD +49.6%
Operating Lease, Liability 1.87M USD
Payments to Acquire Property, Plant, and Equipment 1.33M USD +2981%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -154M USD -115%
Lessee, Operating Lease, Liability, to be Paid 2.1M USD
Property, Plant and Equipment, Gross 17.9M USD +18%
Operating Lease, Liability, Current 606K USD -69.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 398K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 386K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 410K USD
Deferred Tax Assets, Operating Loss Carryforwards 34.7M USD +9.25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.82M USD +94.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 106K USD
Operating Lease, Payments 500K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 616K USD +4.76%
Deferred Tax Assets, Net of Valuation Allowance 649K USD -15.6%
Share-based Payment Arrangement, Expense 26.1M USD +81.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%